Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1996-10-10
|
pubmed:abstractText |
A novel membrane-soluble prodrug of the 5'-monophosphate derivative of 3TC containing a phenyl group and the methyl ester of L-alanine linked to the phosphorus through a phosphoramidate bond with the primary amino moiety (designated Cf 1109) was prepared. The 3TC prodrug proved less potent an inhibitor of HIV-1 and HIV-2 replication in CEM cell cultures than 3TC, but lost only 20-fold antiviral potency in 2'-deoxycytidine kinase-deficient CEM/dCK- cells compared with a more than 2,000-fold decrease of activity of 3TC. In contrast, 3TC and Cf 1109 proved equally highly effective in inhibiting HBV release in supernatants of HBV-transfected Hep G2 2.2.15 cell cultures (50% effective concentration approximately 0.02 microM). Both compounds easily selected for highly resistant HIV-1 strains at a comparable speed of breakthrough. The mutant viruses contained an 184-Ile and/or 184-Val amino acid change in their reverse transcriptase. Our data are suggestive for a relatively poor delivery of 3TC-MP in the intact CEM cells but a remarkably high delivery of 3TC and/or 3TC-MP in the intact Hep G2 2.2.15 cells.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents,
http://linkedlifedata.com/resource/pubmed/chemical/DNA Primers,
http://linkedlifedata.com/resource/pubmed/chemical/Lamivudine,
http://linkedlifedata.com/resource/pubmed/chemical/Reverse Transcriptase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Zalcitabine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0006-291X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
14
|
pubmed:volume |
225
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
363-9
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8753770-Antiviral Agents,
pubmed-meshheading:8753770-Base Sequence,
pubmed-meshheading:8753770-Cell Line,
pubmed-meshheading:8753770-DNA Primers,
pubmed-meshheading:8753770-Drug Resistance, Microbial,
pubmed-meshheading:8753770-HIV-1,
pubmed-meshheading:8753770-Hepatitis B virus,
pubmed-meshheading:8753770-Humans,
pubmed-meshheading:8753770-Lamivudine,
pubmed-meshheading:8753770-Molecular Sequence Data,
pubmed-meshheading:8753770-Mutation,
pubmed-meshheading:8753770-Reverse Transcriptase Inhibitors,
pubmed-meshheading:8753770-Virus Replication,
pubmed-meshheading:8753770-Zalcitabine
|
pubmed:year |
1996
|
pubmed:articleTitle |
Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109.
|
pubmed:affiliation |
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium.
|
pubmed:publicationType |
Journal Article
|